الصفحة الرئيسية>>Signaling Pathways>> Cardiovascular>> Thrombosis>>Thrombin Receptor Peptide Ligand (trifluoroacetate salt)

Thrombin Receptor Peptide Ligand (trifluoroacetate salt) (Synonyms: AFLARAA, Ala-Phe-Leu-Ala-Arg-Ala-Ala)

رقم الكتالوجGC45051

Thrombin receptor peptide ligand is antagonist of the thrombin receptor (EC50s = 16-33 μM to inhibit platelet aggregation in vitro).

Products are for research use only. Not for human use. We do not sell to patients.

Thrombin Receptor Peptide Ligand (trifluoroacetate salt) التركيب الكيميائي

الحجم السعر المخزون الكميّة
1mg
301٫00
متوفر

Tel:(909) 407-4943 Email: sales@glpbio.com

مراجعات العميل

بناء على آراء العملاء.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Thrombin receptor peptide ligand is antagonist of the thrombin receptor (EC50s = 16-33 µM to inhibit platelet aggregation in vitro). It inhibits α-thrombin and platelet aggregation induced by thrombin receptor activating peptide in vitro when used at a concentration of 32 µM but does not affect platelet aggregation induced by ADP or collagen. It also inhibits thrombin- and TRAP-induced proliferation of vascular smooth muscle cells (VSMCs). Thrombin receptor peptide ligand (100 µmol/kg bolus, i.v., plus 900 µmol/kg infusion) inhibits arterial thrombosis in a rabbit model of partial carotid artery occlusion without increasing bleeding time.

مراجعات

Review for Thrombin Receptor Peptide Ligand (trifluoroacetate salt)

Average Rating: 5 ★★★★★ (Based on Reviews and 6 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Thrombin Receptor Peptide Ligand (trifluoroacetate salt)

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.